Revvity Inc/ US7140461093 /
| 12/06/2024 21:59:57 | Chg. +2.90 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 112.60USD | +2.64% | 60,318 Turnover: 6.76 mill. |
-Bid Size: - | -Ask Size: - | 13.89 bill.USD | 0.25% | 20.24 |
GlobeNewswire
03/06
Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire
28/05
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Grea...
GlobeNewswire
09/05
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific N...
GlobeNewswire
19/01
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Pan...
GlobeNewswire
08/01
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
GlobeNewswire
30/11/2023
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
GlobeNewswire
13/11/2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. -...
GlobeNewswire
05/11/2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - ...
GlobeNewswire
18/05/2021
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study...
GlobeNewswire
11/05/2021
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunol...
GlobeNewswire
29/04/2021
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell R...
